Compare MasTec Inc (MTZ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Sana Biotechnology Inc — how do they compare? MasTec Inc trades at $280.16 (market cap $21.90B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: MasTec Inc is far larger — about 19.4× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| MTZ | SANA | |
|---|---|---|
Market Cap | $21.90B | $1.13B |
Sector | Technology | Health |
52-Week High | $437.51 | $5.92 |
52-Week Low | $172.51 | $2.68 |
Enterprise Value | $24.81B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $281.11, up 4.78% over 24 hours, amid strong 2026 performance with record Q2 revenue of $4.37 billion and a $21.4 billion backlog. Technical indicators show a bearish trend with resistance near $283, while fundamentals reflect robust growth—40% EBITDA growth in Q2—though valuation multiples like a P/E of 43.42 suggest premium pricing. Recent news highlights the acquisition of The Superior Group and a $650 million senior notes offering, bolstering infrastructure capabilities.
The outlook is positive, driven by infrastructure demand and raised 2026 guidance, but risks include execution challenges from acquisitions and communications segment delays. Analysts are overwhelmingly bullish with an 88.89% buy rating and a $439.56 consensus target, implying significant upside from current levels.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
